Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
1.
Sensors (Basel) ; 23(22)2023 Nov 16.
Artículo en Inglés | MEDLINE | ID: mdl-38005612

RESUMEN

With the rise in traffic congestion in urban centers, predicting accidents has become paramount for city planning and public safety. This work comprehensively studied the efficacy of modern deep learning (DL) methods in forecasting traffic accidents and enhancing Level-4 and Level-5 (L-4 and L-5) driving assistants with actionable visual and language cues. Using a rich dataset detailing accident occurrences, we juxtaposed the Transformer model against traditional time series models like ARIMA and the more recent Prophet model. Additionally, through detailed analysis, we delved deep into feature importance using principal component analysis (PCA) loadings, uncovering key factors contributing to accidents. We introduce the idea of using real-time interventions with large language models (LLMs) in autonomous driving with the use of lightweight compact LLMs like LLaMA-2 and Zephyr-7b-α. Our exploration extends to the realm of multimodality, through the use of Large Language-and-Vision Assistant (LLaVA)-a bridge between visual and linguistic cues by means of a Visual Language Model (VLM)-in conjunction with deep probabilistic reasoning, enhancing the real-time responsiveness of autonomous driving systems. In this study, we elucidate the advantages of employing large multimodal models within DL and deep probabilistic programming for enhancing the performance and usability of time series forecasting and feature weight importance, particularly in a self-driving scenario. This work paves the way for safer, smarter cities, underpinned by data-driven decision making.

2.
Sensors (Basel) ; 23(13)2023 Jun 25.
Artículo en Inglés | MEDLINE | ID: mdl-37447746

RESUMEN

This paper presents an exploration into the capabilities of an adaptive PID controller within the realm of truck platooning operations, situating the inquiry within the context of Cognitive Radio and AI-enhanced 5G and Beyond 5G (B5G) networks. We developed a Deep Learning (DL) model that emulates an adaptive PID controller, taking into account the implications of factors such as communication latency, packet loss, and communication range, alongside considerations of reliability, robustness, and security. Furthermore, we harnessed a Large Language Model (LLM), GPT-3.5-turbo, to deliver instantaneous performance updates to the PID system, thereby elucidating its potential for incorporation into AI-enabled radio and networks. This research unveils crucial insights for augmenting the performance and safety parameters of vehicle platooning systems within B5G networks, concurrently underlining the prospective applications of LLMs within such technologically advanced communication environments.


Asunto(s)
Comunicación , Lenguaje , Reproducibilidad de los Resultados , Vehículos a Motor , Solución de Problemas
3.
Tech Coloproctol ; 27(9): 739-746, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-36648600

RESUMEN

BACKGROUND: The surgical treatment of choice for rectal neoplasia is total mesorectal excision (TME). The transanal approach enables a better approach in male and obese patients and/or those with a narrow pelvis and in patients with small tumors. Short-term results are comparable with those for laparoscopy or the open approach, but the medium- and long-term oncological data are sparse. The aim of the present study was to evaluate our early experience with transanal TME (TaTME). METHODS: This was a retrospective study conducted on patients who underwent TaTME at our center between August 2013 and April 2017 with a follow-up ≥ 3 years. Histopathology, complications, mortality, neoplastic recurrence and disease-free survival were analyzed. RESULTS: One hundred patients (68 men and 32 women,, median age 66.8 years [range 29.6-91.2 years]) were included. There were 67 T3 cases (67%) with 74 N0 cases (74%), the mesorectal quality was graded optimal for 87.6% and only 2 cases of radial margin involvement were detected (2%). The median follow-up period was 47.6 months (range 11.8-78.9 months). Eighteen cases of recurrence were diagnosed, of which 3 (3%) recurred locally with an average disease-free period of 43.1 months. Overall survival was 80% and mortality due to progression of disease was 13%. CONCLUSIONS: TaTME is a safe surgical procedure with surgical, anatomopathological and oncological results at 3 years (medium-term) comparable with those for the laparoscopic and open approaches. Better monitoring is required with studies of the long-term functional and quality of life outcomes, i.e., at 5 or 10 years.


Asunto(s)
Laparoscopía , Neoplasias del Recto , Cirugía Endoscópica Transanal , Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Recto/cirugía , Recto/patología , Estudios Retrospectivos , Calidad de Vida , Complicaciones Posoperatorias/cirugía , Cirugía Endoscópica Transanal/métodos , Tempo Operativo , Neoplasias del Recto/patología , Laparoscopía/métodos , Resultado del Tratamiento
4.
Artículo en Inglés, Español | MEDLINE | ID: mdl-30738915

RESUMEN

Primary hyperparathyroidism is one of the most frequent endocrine disorders. Its diagnosis is biochemical. Imaging techniques are not useful for the diagnosis of this pathology; they are just tools for pre-surgical localization. In this continuing education, we will analyze the different imaging modalities used in this indication, focusing on Nuclear Medicine. The most commonly used imaging technique in this context is the parathyroid scintigraphy, nowadays double phase protocol with 99mTc-MIBI and the double tracer with 99mTc-MIBI/99mTc-pertechnetate, associated in the first case to SPECT or SPECT/CT, in an early or late phase. The PET/CT with different tracers is showing good results, especially applied to cases of failure in the pre-surgical scintigraphic localization. We expose the results of the morphological imaging techniques as well as the usefulness of combining techniques.


Asunto(s)
Hiperparatiroidismo Primario/diagnóstico por imagen , Cuidados Preoperatorios , Humanos , Hiperparatiroidismo Primario/cirugía , Cintigrafía/métodos
5.
Oncogene ; 36(32): 4670, 2017 08 10.
Artículo en Inglés | MEDLINE | ID: mdl-28368396

RESUMEN

This corrects the article DOI: 10.1038/onc.2016.209.

6.
Oncogene ; 36(3): 429-438, 2017 01 19.
Artículo en Inglés | MEDLINE | ID: mdl-27321178

RESUMEN

Canonical Wnt signaling induces the stabilization of ß-catenin, its translocation to the nucleus and the activation of target promoters. This pathway is initiated by the binding of Wnt ligands to the Frizzled receptor, the association of the LRP5/6 co-receptor and the formation of a complex comprising Dvl-2, Axin and protein kinases CK1α, ɛ, γ and GSK3. Among these, activation of CK1ɛ, constitutively bound to LRP5/6 through p120-catenin, is required for the association of the rest of the components. We describe here that CK1ɛ is activated by the PP2A/PR61ɛ phosphatase. Binding of Wnt ligands promotes the interaction of LRP5/6-associated CK1ɛ with Frizzled-bound PR61ɛ regulatory subunit, facilitating the access of PP2A catalytic subunit to CK1ɛ and its activation, what enables the recruitment of Dvl-2 to the receptor complex and the initiation of the Wnt pathway. Our results uncover the mechanism of activation of the canonical Wnt pathway by its ligands.


Asunto(s)
Quinasa Idelta de la Caseína/metabolismo , Proteína Fosfatasa 2/metabolismo , Receptores Frizzled/metabolismo , Células HEK293 , Células HT29 , Humanos , Vía de Señalización Wnt
7.
Opt Lett ; 40(12): 2850-3, 2015 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-26076278

RESUMEN

In general, there is an inverse relation between the degree of localization of a wave function of a certain class and its transform representation dictated by the scaling property of the Fourier transform. We report that in the case of finite energy Airy wave packets a simultaneous increase in their localization in the direct and transform domains can be obtained as the apodization parameter is varied. One consequence of this is that the far-field diffraction rate of a finite energy Airy beam decreases as the beam localization at the launch plane increases. We analyze the asymptotic properties of finite energy Airy wave functions using the stationary phase method. We obtain one dominant contribution to the long-term evolution that admits a Gaussian-like approximation, which displays the expected reduction of its broadening rate as the input localization is increased.

8.
J Antimicrob Chemother ; 69(9): 2536-40, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24833755

RESUMEN

OBJECTIVES: To present clinical experience with a regimen including abacavir/lamivudine + darunavir/ritonavir in a cohort of HIV-1-infected patients. METHODS: A retrospective, multicentre cohort study, including all consecutive adult HIV-1-infected patients who started abacavir/lamivudine + darunavir/ritonavir from April 2008 to December 2010 and had at least one follow-up visit. The primary endpoint was HIV-1 viral load (VL) <40 copies/mL at week 48. RESULTS: One hundred and eighty-three patients (42 naive and 141 experienced) from 19 hospitals in Spain were studied. The median follow-up was 26.7 (0.5-58.6) months, 79.8% were men, the median age was 47.1 (21.4-80.5) years, 26.2% had AIDS and 38.8% were positive for hepatitis C virus. At baseline, the median CD4 count was 246 cells/mm(3) in naive patients and 393 cells/mm(3) in experienced patients and the median VL was 4.80 and <1.59 log copies/mL, respectively. At week 48, 81.8% of naive patients and 84.2% of experienced patients receiving the regimen reached a VL <40 copies/mL, whereas at 96 weeks this occurred in 90.5% and 92.8%, respectively. CD4 cell count increases at 48 and 96 weeks were +176.5 and +283.5 cells/mm(3) in naive patients and +74.9 and +93 cells/mm(3) in experienced patients, respectively. Overall, 86 (47%) patients discontinued the study regimen, in many cases possibly related to non-medical reasons, such as drug switches to reduce cost or changes in address due to economic constraints. Three patients died of causes unrelated to therapy and 19 (10.4%) discontinued the regimen due to adverse events. CONCLUSIONS: In our cohort, abacavir/lamivudine + darunavir/ritonavir was safe, well tolerated and achieved high rates of virological suppression. In a proportion of patients, discontinuation of this effective regimen was possibly due to non-medical reasons.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa/métodos , Didesoxinucleósidos/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Lamivudine/uso terapéutico , Ritonavir/uso terapéutico , Sulfonamidas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Fármacos Anti-VIH/efectos adversos , Terapia Antirretroviral Altamente Activa/efectos adversos , Estudios de Cohortes , Darunavir , Didesoxinucleósidos/efectos adversos , Combinación de Medicamentos , Femenino , VIH-1/aislamiento & purificación , Humanos , Lamivudine/efectos adversos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Ritonavir/efectos adversos , España , Sulfonamidas/efectos adversos , Resultado del Tratamiento , Carga Viral , Adulto Joven
10.
Curr HIV Res ; 10(6): 513-20, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22716109

RESUMEN

OBJECTIVE: To evaluate long-term outcomes in patients maintaining a nevirapine (NVP)-based regimen. METHODS: Retrospective, multicenter, cohort study including patients currently receiving an NVP regimen that had been started at least 5 years previously. Demographic, clinical, and analytical variables were recorded. RESULTS: Median follow-up was 8.9 (5.7-11.3) years. Baseline characteristics: 74% men, 47 years old, 36% drug users, 40% AIDS, 40% HCV+, 51.4% detectable HIV-1 viral load, CD4 count 395 (4-1,421)/µL, 19% CD4 < 200/µL, 27% ALT grade 1-2, 36% AST grade 1-2. Thirty percent ART-naive, 83%received NVP associated with 2 nucleoside analogues during the study period, and 17% a protease inhibitor. A significant improvement was observed in general health status markers, including hemoglobin, platelets, and albumin, regardless of HCV coinfection. CD4 cell gain was +218 and +322/µL after 6 and 9 years, respectively (+321 and +391 in naive patients). Triglycerides significantly decreased in pretreated patients, whereas the percentage of patients with HDLc < 1.03 mmol/L and LDL-c > 3.37 mmol/L significantly decreased in a subsample with available values. A significant decrease in transaminases, alkaline phosphatase, and Fib4 score was observed, mainly in HCV+ and ARV-naive patients. CONCLUSIONS: In patients who tolerate NVP therapy, (even those with HCV coinfection), long term benefits may be significant in terms of a progressive improvement in general health status markers and CD4 response, a favorable lipid profile, and good liver tolerability.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Fármacos Anti-VIH/administración & dosificación , Hepatitis C/tratamiento farmacológico , Hígado/efectos de los fármacos , Nevirapina/administración & dosificación , Trastornos Relacionados con Sustancias/epidemiología , Síndrome de Inmunodeficiencia Adquirida/sangre , Síndrome de Inmunodeficiencia Adquirida/epidemiología , Recuento de Linfocito CD4 , Colesterol/sangre , Estudios de Cohortes , Coinfección , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Hepatitis C/sangre , Hepatitis C/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , España/epidemiología , Factores de Tiempo , Resultado del Tratamiento , Triglicéridos/sangre , Carga Viral
11.
HIV Med ; 13(8): 488-98, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22416676

RESUMEN

OBJECTIVE: The aim of the study was to investigate changes in plasma biomarkers of cardiovascular risk and lipids in a CD4-guided antiretroviral therapy interruption study. METHODS: This was a substudy of a prospective, randomized, multicentre treatment interruption study. At months 12, 24 and 36, monocyte chemotactic protein-1 (MCP-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), interleukin-6 (IL-6), interleukin-8 (IL-8), soluble CD40 ligand (sCD40L), soluble P-selectin (sP-selectin), and tissue plasminogen activator (t-PA) were measured using a multiplex cytometric bead-based assay. Total cholesterol (total-c), high-density lipoprotein cholesterol (HDL-c) and triglycerides (TG) were determined using standard methods. RESULTS: Fifty-four patients were included in the study [34 in the treatment continuation (TC) arm and 20 in the treatment interruption (TI) arm]. There were no differences at baseline between the groups, except in CD4 cell count, which was higher in the TI arm (P = 0.026), and MCP-1, which was higher in the TC arm (P = 0.039). MCP-1 and sVCAM-1 were increased relative to baseline at the three study time-points in the TI arm, with no changes in the TC arm. Soluble CD40L and sP-selectin were increased at month 36 in both arms, with a greater increase in the TI arm (P = 0.02). t-PA was increased in both arms at the three time-points. Total-c, HDL-c and low-density lipoprotein cholesterol (LDL-c) were decreased in the TI arm at the three time-points, with no changes in the total-c/HDL-c ratio. HIV viral load positively correlated with MCP-1 at months 12 and 24. Regression analysis showed a significant negative association of HDL-c with MCP-1 and sVCAM-1. CONCLUSIONS: A significant increase in cardiovascular risk biomarkers persisting over the prolonged study period was seen in the TI arm. This factor may contribute to the increased cardiovascular risk observed in previous studies.


Asunto(s)
Antirretrovirales/administración & dosificación , Enfermedades Cardiovasculares/fisiopatología , Citocinas/sangre , Infecciones por VIH/tratamiento farmacológico , Lípidos/sangre , Adulto , Anciano , Biomarcadores/sangre , Recuento de Linfocito CD4 , Femenino , Citometría de Flujo/métodos , Infecciones por VIH/inmunología , Infecciones por VIH/virología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Análisis de Regresión , España , Carga Viral
13.
Opt Lett ; 32(9): 1126-8, 2007 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-17410257

RESUMEN

Reflection and refraction of spatial solitons at dielectric interfaces, accommodating arbitrarily angles of incidence, is studied. Analysis is based on Helmholtz soliton theory, which eliminates the angular restriction associated with the paraxial approximation. A novel generalization of Snell's law is discovered that is valid for collimated light beams and the entire angular domain. Our new theoretical predictions are shown to be in excellent agreement with full numerical simulations. New qualitative features of soliton refraction and limitations of previous paraxial analyses are highlighted.

14.
Eur J Cancer ; 42(16): 2751-6, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17027257

RESUMEN

BACKGROUND: This was a feasibility study of the combination of Exemestane and the cyclooxygenase-2 (COX-2) inhibitor Celecoxib in advanced breast cancer. PATIENTS AND METHODS: Post-menopausal women with histologically proven, hormone receptor positive, advanced breast cancer who had progressive disease, normal blood counts, liver and renal function were eligible. Exemestane was given at a dose of 25 mg daily and Celecoxib at a dose of 400 mg bd. Responses were assessed according to RECIST criteria and toxicity was accessed according to CTC. The primary end-point was the percentage of patients who had neither discontinued therapy nor progressed at 6 months ('treatment successes'). RESULTS: Fifty-three eligible patients were enrolled. Of 30 patients with target lesions, 4 (13%) had a complete response (CR), 12 (40%) a partial response (PR) and 5 (17%) stable disease (SD). The best response in 18 of the 23 patients with no target lesions at baseline was stable disease. The clinical benefit (CR, PR+SD) for the whole group was therefore 39/53 (74%). The 'treatment success' rate was 60%. There were two non-malignant deaths which may have been associated with treatment. CONCLUSION: The combination of Exemestane and Celecoxib shows promising activity and tolerability and these results support the use of this combination in phase III clinical trials of short duration treatments.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Adulto , Anciano , Androstadienos/administración & dosificación , Androstadienos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Celecoxib , Inhibidores de la Ciclooxigenasa 2/administración & dosificación , Inhibidores de la Ciclooxigenasa 2/efectos adversos , Supervivencia sin Enfermedad , Estudios de Factibilidad , Femenino , Humanos , Persona de Mediana Edad , Posmenopausia , Pirazoles/administración & dosificación , Pirazoles/efectos adversos , Calidad de Vida , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos , Resultado del Tratamiento
16.
J Am Acad Dermatol ; 51(5 Suppl): S166-8, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15577761

RESUMEN

Extraskeletal osteosarcoma represents approximately 1% of soft tissue sarcomas and approximately 4% of all osteosarcomas. It is therefore much rarer than osteosarcoma arising primarily in bone. Skin as a primary site has seldom been reported. This report describes an extraskeletal osteosarcoma of the skin under a previously electrodessicated actinic keratosis.


Asunto(s)
Desecación/métodos , Queratosis/terapia , Osteosarcoma/patología , Neoplasias Cutáneas/patología , Anciano , Anciano de 80 o más Años , Neoplasias Faciales/patología , Neoplasias Faciales/cirugía , Femenino , Humanos , Queratosis/patología , Osteosarcoma/cirugía , Pronóstico , Neoplasias Cutáneas/cirugía
17.
J Eur Acad Dermatol Venereol ; 18(2): 199-200, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15009305

RESUMEN

Necrobiosis lipoidica (NL) is a disease of collagen. Squamous cell carcinomas developing in areas of chronic ulceration and scarring have been well documented in a variety of skin diseases but rarely in areas of necrobiosis lipoidica. The case history of a 76-year-old female is presented, whose squamous cell carcinoma appeared 30 years after the diagnosis of necrobiosis lipoidica. The clinical and histopathological picture is described, stressing the importance of the unusual association of the two pathologies in the prognostic.


Asunto(s)
Carcinoma de Células Escamosas/complicaciones , Necrobiosis Lipoidea/complicaciones , Neoplasias Cutáneas/complicaciones , Anciano , Carcinoma de Células Escamosas/patología , Femenino , Humanos , Neoplasias Cutáneas/patología
19.
Ann Oncol ; 15(1): 79-87, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14679124

RESUMEN

BACKGROUND: A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients. PATIENTS AND METHODS: Four-hundred and eighty-five patients with node-positive operable disease were randomized to receive tamoxifen (20 mg/day) concomitantly (CON) or sequentially (SEQ) to EC chemotherapy (epirubicin 75 mg/m(2) + cyclophosphamide 600 mg/m(2) on day 1, every 21 days for four cycles). RESULTS: In the 474 fully evaluable patients there were 96 events; eight being second neoplasms and 88 being related to the breast cancer. Of these, 48 of 88 occurred in the CON arm and 40 of 88 in the SEQ arm. The Kaplan-Meier estimation of disease-free survival (DFS) at 5 years was 70% in the CON and 75% in the SEQ group (log-rank test, P = 0.43). Adjusted hazard ratio for treatment was 1.11 (95% confidence interval 0.71-1.73; P = 0.64). CONCLUSION: This study fails to show an advantage of one treatment arm over the other, but a trend, albeit non-significant, appears to favor the sequential addition of tamoxifen to epirubicin + cyclophosphamide and, as such, warrants further investigation.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Anciano , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/efectos adversos , Antineoplásicos Alquilantes/administración & dosificación , Antineoplásicos Alquilantes/efectos adversos , Antineoplásicos Hormonales/administración & dosificación , Antineoplásicos Hormonales/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Quimioterapia Adyuvante/métodos , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Supervivencia sin Enfermedad , Interacciones Farmacológicas , Epirrubicina/administración & dosificación , Epirrubicina/efectos adversos , Femenino , Humanos , Persona de Mediana Edad , Metástasis de la Neoplasia , Posmenopausia , Tamoxifeno/administración & dosificación , Tamoxifeno/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...